Alcon, Inc. (ALC)
| Market Cap | 36.84B |
| Revenue (ttm) | 6.83B |
| Net Income (ttm) | -531.00M |
| Shares Out | 499.70M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | 38.61 |
| Dividend | $0.11 |
| Dividend Yield | 0.15% |
| Trading Day | April 16 |
| Last Price | $74.18 |
| Previous Close | $74.13 |
| Change ($) | 0.05 |
| Change (%) | 0.07% |
| Day's Open | 74.00 |
| Day's Range | 73.65 - 74.30 |
| Day's Volume | 453,915 |
| 52-Week Range | 49.74 - 76.26 |
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.
Alcon (NYSE:ALC) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0 Somewhat Bullish 0 2 0 0 Indifferent 0 0 0 0 Som...
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon to Host Virtual Capital Markets Day on March 24
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon's Sue-Jean Lin Wins 2021 Dallas CIO of the Year
Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 8.89% over the past year to $0.41, which were in line w...
GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2020 Results
Alcon, Inc. (ALC) Presents at JPMorgan Healthcare Conference - (Transcript)
Eye-care devices market is an attractive end-market supported by secular growth trends such as aging population, increased myopia prevalence, and innovation in products leading to better outcomes for pa...
Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript
Unable to provide full-year guidance due to difficult market conditions, Alcon CEO says
Alcon CEO David Endicott discusses the company's third-quarter earnings.
Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 15.22% year over year to $0.39, which beat the estimat...
Alcon Inc. (ALC) CEO David Endicott on Q2 2020 Results - Earnings Call Transcript
Alcon Inc. (ALC) CEO David Endicott on Q1 2020 Results - Earnings Call Transcript
Alcon, Inc. (ALC) CEO David Endicott on Q4 2019 Results - Earnings Call Transcript
The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.
About ALC
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR sur... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1945 |
| CEO David J. Endicott | Employees 23,655 |
| Stock Exchange NYSE | Ticker Symbol ALC |
Financial Performance
In 2020, Alcon's revenue was $6.83 billion, a decrease of -8.99% compared to the previous year's $7.51 billion. Losses were -$531.00 million, -19.05% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Alcon is 76.45, which is an increase of 3.06% from the latest price.